Balyasny Asset Management LLC Reata Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$22.15 - $42.11 $675,730 - $1.28 Million	-30,507 Reduced 99.96%	11 $0
Q3 2022 Nov 14, 2022	SELL	$19.41 - $36.49 $1.28 Million - $2.41 Million	-66,080 Reduced 68.41%	30,518 $767,000
Q2 2022 Aug 15, 2022	BUY	$20.71 - $36.5 $1.81 Million - $3.19 Million	87,481 Added 959.54%	96,598 $2.94 Million
Q1 2022 May 16, 2022	SELL	$24.12 - $39.6 $3.27 Million - $5.36 Million	-135,404 Reduced 93.69%	9,117 $299,000
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $3.7 Million - $16 Million	144,521 New	144,521 $3.81 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $8.52 Million - $16.5 Million	-108,809 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $10.3 Million - $14.5 Million	108,809 New	108,809 $10.8 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $539,126 - $975,532	-5,284 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $494,212 - $863,088	5,284 New	5,284 $515,000
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $491,938 - $687,701	-3,895 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $483,603 - $964,947	3,895 New	3,895 $562,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.